Oxaliplatin
Disease Related To Solid Organ Transplantation
Explore 18 assets in Disease Related To Solid Organ Transplantation →Floatz Rating
B58/100
Confidence
Indicative
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01125020CT.gov Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Disease Related To Solid Organ Transplantation
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Oxaliplatin (this asset) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P3 | B · 58 |
| Tacrolimus | The Second Hospital of Tangshan | P4 | BBB |
| Angiotensin Ii | University of California, San Francisco | P4 | BBB |
| Everolimus | Novartis Pharmaceuticals | P3 | BB |
| Equine Atg | University Hospital, Toulouse | P4 | BB |
| Envarsus Product | University of Alberta | P4 | BB |
| Sitagliptin | University Health Network, Toronto | P4 | BB |
| Semaglutide | University Health Network, Toronto | P4 | BB |
| Noradrenaline | University of California, Los Angeles | P4 | BB |
+26 more in the Disease Related To Solid Organ Transplantation cohort
Other indications for Oxaliplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 76 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
| Colorectal Neoplasm | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Oxaliplatin in Disease Related To Solid Organ Transplantation. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/oxaliplatin-disease-related-to-solid-organ-transplantation
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →